Triple-negative breast cancer is a subtype that is defined by its lack of hormone receptors (ie, estrogen/progesterone), as well as a lack of overexpression/amplification of human epidermal growth factor receptor-2 (HER2). These breast tumors tend to be more aggressive, developing more often in patients who are premenopausal, and recurring earlier after diagnosis and treatment than other subtypes. Triple-negative breast cancer represents roughly 15%-20% of all breast tumors and carries the worst prognosis when it becomes metastatic, compared with other subtypes. Until very recently, single-agent chemotherapy or combinations of cytotoxic agents were the only therapies available to treat advanced or metastatic triple-negative breast cancer. A few new classes of therapeutic agents and approaches have been approved in the past 5 years; however, more effective, less toxic options are urgently needed.
What do you know about the management of advanced or metastatic triple-negative breast cancer? Test yourself with this quick quiz.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Tanya Gupta. Fast Five Quiz: Management of Advanced or Metastatic Triple-Negative Breast Cancer - Medscape - Jul 27, 2023.